Cargando…

SAT-038 Ambulatory Blood Pressure Increases in Hypogonadal Men Who Develop Increases in Hematocrit on Oral Testosterone Undecanoate

There is concern that testosterone replacement therapies might increase blood pressure (BP) with chronic use. Testosterone undecanoate is a novel oral testosterone therapy under development for the treatment of male hypogonadism. We studied the effects of testosterone undecanoate (225 mg twice daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dobs, Adrian Sandra, White, William B, Carson, Culley, DelConte, Anthony, Khera, Mohit, Miner, Martin, Shahid, Muhamma, Papangkorn, Kongnara, Kim, Kilyoung, Chidambaram, Nachiappan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208663/ http://dx.doi.org/10.1210/jendso/bvaa046.957

Ejemplares similares

SAT-052 A Novel Oral Testosterone Therapy (TLANDO) Safely Restores Testosterone to Eugonadal Levels with Fixed Dose Treatment
por: DelConte, Anthony, et al.
Publicado: (2020)

A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism
por: DelConte, Anthony, et al.
Publicado: (2022)

TLANDO, a Novel Oral TRT, Improves Sexual and Mental Domain Outcomes in Hypogonadal Men
por: Bruno, Benjamin J, et al.
Publicado: (2021)

Low Testosterone in Males May Warrant Liver Health Assessment and Intervention
por: DelConte, Anthony, et al.
Publicado: (2021)

Efficacy and Safety of TLANDO, A Novel Oral Easy to Prescribe and Use TRT Option
por: Papangkorn, Kongnara, et al.
Publicado: (2021)

SAT-044 Treatment of Hypogonadal Men with a New Oral Testosterone Undecanoate (TU) Formulation Improves Psychosexual, Well-Being and Body Composition and Bone Density Parameters
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism
por: Yadav, Subhash Chandra, et al.
Publicado: (2019)

PMON267 Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Softgel (JATENZO®)
por: Swerdloff, Ronald, et al.
Publicado: (2022)

SAT-LB5 Prevalence of Hypogonadism in Young Obese Males
por: Halappanavar, Anup, et al.
Publicado: (2020)

Recovery of Male Reproductive Endocrine Function Following Prolonged Injectable Testosterone Undecanoate Treatment
por: Shankara-Narayana, Nandini, et al.
Publicado: (2021)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

LPCN 1144 Resolves NAFLD in Hypogonadal Males
por: Albhaisi, Somaya, et al.
Publicado: (2020)

SAT-LB004 Therapeutic Potential of LPCN 1144 in NAFLD and NASH
por: Baker, Jonathan, et al.
Publicado: (2019)

Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men
por: White, William B., et al.
Publicado: (2021)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

SAT-LB6 First Human Trial of an Oral Native Testosterone Shows Physiological Levels of Testosterone and Dht in Both Fasted and Fed State in Hypogonadal Men
por: Newell-Price, John D C, et al.
Publicado: (2020)

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
por: Swerdloff, Ronald S., et al.
Publicado: (2020)

OR18-4 Beneficial Effect on Sperm Production of Leflutrozole in Men with Obesity-Associated Secondary Hypogonadotropic Hypogonadism: Results from a Phase II Study
por: Jones, Thomas, et al.
Publicado: (2019)

SAT-034 The Effect of Natesto on Spermatogenesis, Reproductive Hormones, and Hypogonadal Symptoms. A Phase IV Study
por: Masterson, Thomas A, et al.
Publicado: (2020)

SAT-049 Testosterone Therapy Reduces Inflammatory Activation of Human Monocytes in Hypogonadal Type-2 Diabetic Men as a Potential Mechanism to Improve Atherosclerosis
por: Bateman, Lauren, et al.
Publicado: (2020)

SUN-227 Monitoring Testosterone (T) Levels in Men Receiving Oral Testosterone Undecanoate (TU): Challenges Due to Post-Collection Conversion of TU-to-T and a Path Forward
por: Swerdloff, Ronald, et al.
Publicado: (2019)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

SUN-038 Social and Psychological Aspects of Partial Androgen Insensitivity Syndrome, Therapeutic Challenges
por: Masood, Faryal T, et al.
Publicado: (2020)

SAT-030 The Barnsley Diabetes Hypogonadal Questionnaire (BDHQ) - Validation for the Clinical Use to Support the Diagnosis of Testosterone Deficiency in Men with Type 2 Diabetes (T2D)
por: Mumdzic, Enis, et al.
Publicado: (2020)

Corrigendum to a new oral testosterone undecanoate (TU) therapy comes of age for the treatment of hypogonadal men
Publicado: (2021)

Safety Analysis of an Oral Testosterone Undecanoate (TU) Formulation Following 2 Years of Administration in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2021)

Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males
por: Pastuszak, Alexander W., et al.
Publicado: (2021)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

SAT-051 Effects of Testosterone Replacement on Glycemic Control and Other Cardiovascular Risk Factors in Hypogonadal Men with Uncontrolled Type 2 Diabetes (Stride Study): Design, Implementation and Baseline Data
por: Rao, Preethi Mohan, et al.
Publicado: (2020)

037 Is Oral Testosterone a Potential Treatment for COVID-19 in Men?
por: Papangkorn, K., et al.
Publicado: (2021)

SUN-LB038 Rate and Extent of Testicular Function Recovery after Ceasing Non-Prescribed Androgen Abuse
por: Shankara Narayana, Nandini, et al.
Publicado: (2019)

ODP412 High Frequency of Erythrocytosis in Hypogonadal Men on Testosterone Replacement Therapy
por: Pérez-Luis, Jesús, et al.
Publicado: (2022)

OR25-06 The Effect of Testosterone Replacement Therapy on NAFLD in Elderly Hypogonadal Men
por: Seung Lee, Hae, et al.
Publicado: (2023)

Impact of Testosterone Therapy on Hematocrit and Polycythemia: Evaluation of Data From Two Ongoing Open-Label Randomized Single-Center Clinical Trials
por: Gonzalez, Daniel, et al.
Publicado: (2021)

The complex relation between obstructive sleep apnoea syndrome, hypogonadism and testosterone replacement therapy
por: Graziani, Andrea, et al.
Publicado: (2023)

MON-LB038 Reduced Exercise Endurance And Skeletal Muscle Alterations In A Prenatally Androgenized Rat Model For Polycystic Ovary Syndrome
por: DeChick, Auryana, et al.
Publicado: (2019)

FRI433 Hypogonadism In Males With Adrenoleukodystrophy
por: Alcantara, Jonanlis Ramirez, et al.
Publicado: (2023)

SAT-038 Physiology of Mice Lacking All Four Adenosine Receptors
por: Xiao, Cuiying, et al.
Publicado: (2019)

SAT-037 Effect of Weight on Serum Testosterone with Subcutaneous Testosterone Enanthate in Men with Testosterone Deficiency
por: Bhattacharya, Rajib, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_75hq17pff86eb1ldrtkmk59a1q